These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
258 related articles for article (PubMed ID: 11257149)
1. Increased urinary pyridinoline cross-link compounds of collagen in patients with systemic sclerosis and Raynaud's phenomenon. Istok R; Czirják L; Lukác J; Stancíková M; Rovenský J Rheumatology (Oxford); 2001 Feb; 40(2):140-6. PubMed ID: 11257149 [TBL] [Abstract][Full Text] [Related]
2. Serum TIMP-1, TIMP-2, and MMP-1 in patients with systemic sclerosis, primary Raynaud's phenomenon, and in normal controls. Young-Min SA; Beeton C; Laughton R; Plumpton T; Bartram S; Murphy G; Black C; Cawston TE Ann Rheum Dis; 2001 Sep; 60(9):846-51. PubMed ID: 11502611 [TBL] [Abstract][Full Text] [Related]
3. Measurement of cold challenge responses in primary Raynaud's phenomenon and Raynaud's phenomenon associated with systemic sclerosis. O'Reilly D; Taylor L; el-Hadidy K; Jayson MI Ann Rheum Dis; 1992 Nov; 51(11):1193-6. PubMed ID: 1466594 [TBL] [Abstract][Full Text] [Related]
4. Differences in red cell behaviour between patients with Raynaud's phenomenon and systemic sclerosis and patients with Raynaud's disease. Rustin MH; Kovacs IB; Sowemimo-Coker SO; Maddison PJ; Kirby JD Br J Dermatol; 1985 Sep; 113(3):265-72. PubMed ID: 3877518 [TBL] [Abstract][Full Text] [Related]
5. The Relationship between Smoking, Raynaud's Phenomenon, Digital Ulcers, and Skin Thickness in the Waikato Systemic Sclerosis Cohort. Silva C; Solanki KK; White DHN Rheumatol Immunol Res; 2022 Jun; 3(2):84-89. PubMed ID: 36465326 [TBL] [Abstract][Full Text] [Related]
6. Increased urinary F2-isoprostanes in systemic sclerosis, but not in primary Raynaud's phenomenon: effect of cold exposure. Cracowski JL; Carpentier PH; Imbert B; Cachot S; Stanke-Labesque F; Bessard J; Bessard G Arthritis Rheum; 2002 May; 46(5):1319-23. PubMed ID: 12115239 [TBL] [Abstract][Full Text] [Related]
7. [Botulinum toxin type A contribution in the treatment of Raynaud's phenomenon due to systemic sclerosis]. Serri J; Legré R; Veit V; Guardia C; Gay AM Ann Chir Plast Esthet; 2013 Dec; 58(6):658-62. PubMed ID: 22204894 [TBL] [Abstract][Full Text] [Related]
8. Digital ulcers and cutaneous subsets of systemic sclerosis: Clinical, immunological, nailfold capillaroscopy, and survival differences in the Spanish RESCLE Registry. Tolosa-Vilella C; Morera-Morales ML; Simeón-Aznar CP; Marí-Alfonso B; Colunga-Arguelles D; Callejas Rubio JL; Rubio-Rivas M; Freire-Dapena M; Guillén-Del Castillo A; Iniesta-Arandia N; Castillo-Palma MJ; Egurbide-Arberas M; Trapiellla-Martínez L; Vargas-Hitos JA; Todolí-Parra JA; Rodriguez-Carballeira M; Marin-Ballvé A; Pla-Salas X; Rios-Blanco JJ; Fonollosa-Pla V; Semin Arthritis Rheum; 2016 Oct; 46(2):200-208. PubMed ID: 27312381 [TBL] [Abstract][Full Text] [Related]
9. Time to diagnosis in systemic sclerosis: is sex a factor? Hudson M; Thombs B; Baron M; Arthritis Rheum; 2009 Feb; 61(2):274-8. PubMed ID: 19177534 [TBL] [Abstract][Full Text] [Related]
11. Autonomic nervous system dysfunction in sclerodermic and primary Raynaud's phenomenon. Pancera P; Sansone S; Presciuttini B; Montagna L; Cerù S; Lunardi C; Lechi A Clin Sci (Lond); 1999 Jan; 96(1):49-57. PubMed ID: 9857106 [TBL] [Abstract][Full Text] [Related]
12. Peripheral vasculopathy in patients with systemic sclerosis: difference in limited and diffuse subset of disease. Ostojić P; Damjanov N; Pavlov-Dolijanovic S; Radunović G Clin Hemorheol Microcirc; 2004; 31(4):281-5. PubMed ID: 15567898 [TBL] [Abstract][Full Text] [Related]
13. A randomised double-blind trial of diltiazem in the treatment of Raynaud's phenomenon. Kahan A; Amor B; Menkes CJ Ann Rheum Dis; 1985 Jan; 44(1):30-3. PubMed ID: 3882061 [TBL] [Abstract][Full Text] [Related]
14. Von Willebrand factor, thrombomodulin, thromboxane, beta-thromboglobulin and markers of fibrinolysis in primary Raynaud's phenomenon and systemic sclerosis. Herrick AL; Illingworth K; Blann A; Hay CR; Hollis S; Jayson MI Ann Rheum Dis; 1996 Feb; 55(2):122-7. PubMed ID: 8712862 [TBL] [Abstract][Full Text] [Related]
15. Clinical significance of serum retinol binding protein-4 levels in patients with systemic sclerosis. Toyama T; Asano Y; Takahashi T; Aozasa N; Akamata K; Noda S; Taniguchi T; Ichimura Y; Sumida H; Tamaki Z; Masui Y; Tada Y; Sugaya M; Sato S; Kadono T J Eur Acad Dermatol Venereol; 2013 Mar; 27(3):337-44. PubMed ID: 22211766 [TBL] [Abstract][Full Text] [Related]
16. Plasma adrenomedullin and endothelin-1 levels are reduced and Raynaud's phenomenon improved by daily tadalafil administration in male patients with systemic sclerosis. Rosato E; Letizia C; Proietti M; Aversa A; Menghi G; Rossi C; Torella E; Cotesta D; Petramala L; Bruzziches R; Spera G; Pisarri S; Salsano F J Biol Regul Homeost Agents; 2009; 23(1):23-9. PubMed ID: 19321043 [TBL] [Abstract][Full Text] [Related]
17. Effect of clonazepam on Raynaud's phenomenon and fingertip ulcers in scleroderma. Colakoğlu M; Cobankara V; Akpolat T Ann Pharmacother; 2007 Sep; 41(9):1544-7. PubMed ID: 17666574 [TBL] [Abstract][Full Text] [Related]
19. Raynaud's phenomenon and systemic sclerosis. Generini S; Kahaleh B; Matucci-Cerinic M; Pignone A; Lombardi A; Ohtsuka T Ann Ital Med Int; 1996; 11(2):125-31. PubMed ID: 8974438 [TBL] [Abstract][Full Text] [Related]
20. Biosynthesis of thromboxane in patients with systemic sclerosis and Raynaud's phenomenon. Reilly IA; Roy L; Fitzgerald GA Br Med J (Clin Res Ed); 1986 Apr; 292(6527):1037-9. PubMed ID: 3083991 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]